Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
AstraZeneca
Express Scripts
Colorcon
Johnson and Johnson

Last Updated: September 27, 2022

EYLEA Drug Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Tradename: EYLEA
Recent Litigation for EYLEA

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Novartis Pharma AG v. Regeneron Pharmaceuticals, Inc.2020-06-19

See all EYLEA litigation

PTAB Litigation
PetitionerDate
Regeneron Pharmaceuticals, Inc.2021-04-16
Regeneron Pharmaceuticals, Inc.2020-07-16

See all EYLEA litigation

Pharmacology for EYLEA
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for EYLEA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for EYLEA Derived from Company Disclosures

These patents were obtained from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Patent No. Estimated Patent Expiration Source
Regeneron Pharmaceuticals, Inc. EYLEA aflibercept Injection 125387 See Plans and Pricing 2019-06-08 Company disclosures
Regeneron Pharmaceuticals, Inc. EYLEA aflibercept Injection 125387 See Plans and Pricing 2039-02-26 Company disclosures
Regeneron Pharmaceuticals, Inc. EYLEA aflibercept Injection 125387 See Plans and Pricing 2039-02-26 Company disclosures
Regeneron Pharmaceuticals, Inc. EYLEA aflibercept Injection 125387 See Plans and Pricing 2039-03-29 Company disclosures
Regeneron Pharmaceuticals, Inc. EYLEA aflibercept Injection 125387 See Plans and Pricing 2019-06-08 Company disclosures
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Patent No. >Estimated Patent Expiration >Source

3) Low Certainty: US Patents for EYLEA Derived from Patent Text Search

These patents were obtained by searching patent claims

Supplementary Protection Certificates for EYLEA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
CA 2013 00020 Denmark See Plans and Pricing
132013902154380 Italy See Plans and Pricing PRODUCT NAME: AFLIBERCEPT(EYLEA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/12/797/001-002, 20121122
SPC/GB13/028 United Kingdom See Plans and Pricing PRODUCT NAME: AFLIBERCEPT; REGISTERED: UK EU/1/12/797/001 20121122; UK EU/1/12/797/002 20121122
PA2013009,C1183353 Lithuania See Plans and Pricing PRODUCT NAME: AFLIBERCEPTUM; REGISTRATION NO/DATE: EU/1/12/797/001, 2012 11 22 EU/1/12/797/002, 2012 11 22 EU/1/12/814 20130201
2013C/029 Belgium See Plans and Pricing PRODUCT NAME: AFLIBERCEPT; AUTHORISATION NUMBER AND DATE: EU/1/12/197/001 20121126
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKinsey
Harvard Business School
Dow
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.